Association of Mean Platelet Volume With Risk of Stroke Among 3134 Individuals With History of Cerebrovascular Disease

Background and Purpose— Mean platelet volume (MPV) is positively associated with measures of platelet activity and may be a useful indicator of the risk of vascular events in a variety of patient groups. Methods— The association of MPV with the risk of stroke was assessed in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). All participants had a history of cerebrovascular disease at baseline, and analyses were adjusted for the effects of potential confounders. Results— The study followed 3134 individuals for an average of 3.9 years (mean age, 65 years; 71% male; average MPV, 10.0 fL). Three hundred eighty-three individuals had 402 stroke events, and 160 had major coronary events. MPV was positively associated with the risk of stroke, with an 11% increased relative risk (95% CI, 3% to 19%) of stroke per femtoliter greater MPV. There was no clear association of MPV with the risk of major coronary events (9% decreased relative risk; 95% CI, −23% to 7%). Perindopril did not alter MPV. Conclusions— MPV is an independent predictor of the risk of stroke among individuals with a history of stroke or transient ischemic attack. The measurement of MPV may add useful prognostic information for clinicians managing patients with a history of cerebrovascular disease.

[1]  K. Huber,et al.  Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease , 2002, British journal of haematology.

[2]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[3]  P. Bath,et al.  Prothrombotic megakaryocyte and platelet changes in hypertension are reversed following treatment: a pilot study , 2001, Platelets.

[4]  B. Neal.  The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[5]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[6]  D. Mikhailidis,et al.  Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan , 2000, Journal of Human Hypertension.

[7]  S. MacMahon,et al.  PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. , 2000, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[8]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[9]  PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee. , 1999, Journal of hypertension.

[10]  P. Osuna,et al.  Influencia del volumen plaquetario medio sobre el pronóstico a corto plazo del infarto agudo de miocardio , 1998 .

[11]  G. Zoppo.  The role of platelets in ischemic stroke , 1998 .

[12]  G. D. del Zoppo.  The role of platelets in ischemic stroke , 1998, Neurology.

[13]  R. Leibel,et al.  Genetic Defects in the Control of Growth Hormone Secretion , 1998, Hormone Research in Paediatrics.

[14]  H. Kratochvílová,et al.  Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. , 1998, Platelets.

[15]  P. L. Sánchez Fernández,et al.  [The effect of the mean platelet volume on the short-term prognosis of acute myocardial infarct]. , 1998, Revista espanola de cardiologia.

[16]  P. Bath,et al.  The relationship between mean platelet volume, stroke subtype and clinical outcome. , 1998, Platelets.

[17]  L. Hansson.  Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[18]  P. Bath,et al.  Platelet size: measurement, physiology and vascular disease. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[19]  P. Elwood,et al.  Cigarette Smoking Sensitizes and Desensitizes Impedance-measured ADP-induced Platelet Aggregation in Whole Blood , 1995, Thrombosis and Haemostasis.

[20]  P. Langhorne,et al.  Platelet size in stroke patients. , 1995, Stroke.

[21]  G. MacGregor,et al.  Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. , 1994, Clinical science.

[22]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[23]  T. Trinick,et al.  Mean platelet volume in diabetes mellitus. , 1993, The Quarterly journal of medicine.

[24]  P. Bath,et al.  The Routine Measurement of Platelet Size Using Sodium Citrate Alone as the Anticoagulant , 1993, Thrombosis and Haemostasis.

[25]  J. Carter,et al.  Platelet volume: laboratory measurement and clinical application. , 1993, Blood reviews.

[26]  L. Michalis,et al.  Influence of platelet size before coronary angioplasty on subsequent restenosis , 1993, European journal of clinical investigation.

[27]  P. Bath,et al.  Platelets and Megakaryocytes in Vascular Disease , 1996 .

[28]  M. Burr,et al.  Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.

[29]  S. Kjeldsen,et al.  Platelet Function During Antihypertensive Treatment with Quinapril, a Novel Angiotensin Converting Enzyme Inhibitor , 1991, Journal of cardiovascular pharmacology.

[30]  A. Herman.  Antithrombotics : pathophysiological rationale for pharmacological interventions , 1991 .

[31]  H. Tohgi,et al.  Platelet volume, aggregation, and adenosine triphosphate release in cerebral thrombosis. , 1991, Stroke.

[32]  E. Romagnoli,et al.  Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction , 1990, Journal of internal medicine.

[33]  I. Hjermann,et al.  Increased Platelet Size and Release Reaction in Essential Hypertension , 1987, Journal of hypertension.

[34]  E. Trowbridge,et al.  The routine measurement of platelet volume: a comparison of light-scattering and aperture-impedance technologies. , 1985, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.

[35]  E. Trowbridge,et al.  Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. , 1985, Clinical science.

[36]  H. A. Cameron,et al.  Platelet size in myocardial infarction. , 1983, British medical journal.